| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphangioleiomyomatosis | 12 | 2023 | 35 | 3.150 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 4 | 10 | 2023 | 23 | 2.690 |
Why?
|
| Acute Lung Injury | 11 | 2022 | 288 | 2.520 |
Why?
|
| Neutrophils | 27 | 2020 | 1234 | 2.330 |
Why?
|
| Lung | 31 | 2023 | 4065 | 2.110 |
Why?
|
| Pulmonary Fibrosis | 6 | 2022 | 400 | 1.980 |
Why?
|
| Transforming Growth Factor beta | 7 | 2022 | 480 | 1.730 |
Why?
|
| Matrix Metalloproteinase 3 | 11 | 2022 | 28 | 1.680 |
Why?
|
| Protein Tyrosine Phosphatases | 10 | 2023 | 171 | 1.620 |
Why?
|
| Fibroblasts | 18 | 2023 | 989 | 1.600 |
Why?
|
| Protein-Tyrosine Kinases | 6 | 2018 | 434 | 1.590 |
Why?
|
| Signal Transduction | 34 | 2020 | 5065 | 1.580 |
Why?
|
| Focal Adhesions | 14 | 2018 | 44 | 1.330 |
Why?
|
| Lung Diseases | 4 | 2023 | 768 | 1.210 |
Why?
|
| Leukocyte Elastase | 7 | 2013 | 76 | 1.210 |
Why?
|
| Interleukin-1 | 15 | 2020 | 963 | 1.180 |
Why?
|
| Thorax | 3 | 2022 | 47 | 1.170 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 2023 | 38 | 1.130 |
Why?
|
| Respiration Disorders | 2 | 2018 | 77 | 0.990 |
Why?
|
| Epithelial Cells | 11 | 2021 | 1093 | 0.960 |
Why?
|
| Receptor, PAR-1 | 3 | 2009 | 16 | 0.860 |
Why?
|
| Phagocytosis | 11 | 2011 | 379 | 0.860 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 4 | 2022 | 653 | 0.860 |
Why?
|
| Birt-Hogg-Dube Syndrome | 1 | 2023 | 8 | 0.830 |
Why?
|
| Animals | 74 | 2023 | 36768 | 0.800 |
Why?
|
| Apoptosis | 10 | 2010 | 2548 | 0.790 |
Why?
|
| Respiratory Mucosa | 6 | 2013 | 322 | 0.770 |
Why?
|
| Cysts | 1 | 2023 | 111 | 0.770 |
Why?
|
| Transendothelial and Transepithelial Migration | 2 | 2013 | 31 | 0.760 |
Why?
|
| Particulate Matter | 6 | 2022 | 312 | 0.760 |
Why?
|
| Congresses as Topic | 1 | 2023 | 233 | 0.730 |
Why?
|
| beta Catenin | 3 | 2013 | 251 | 0.730 |
Why?
|
| Cells, Cultured | 26 | 2020 | 4194 | 0.730 |
Why?
|
| Mice | 46 | 2023 | 17731 | 0.690 |
Why?
|
| Pneumonia | 8 | 2018 | 638 | 0.670 |
Why?
|
| Societies, Medical | 3 | 2023 | 820 | 0.650 |
Why?
|
| rac1 GTP-Binding Protein | 6 | 2012 | 56 | 0.640 |
Why?
|
| Respiratory Tract Diseases | 3 | 2022 | 187 | 0.620 |
Why?
|
| Bleomycin | 6 | 2022 | 247 | 0.610 |
Why?
|
| Humans | 108 | 2023 | 136783 | 0.600 |
Why?
|
| Proto-Oncogene Proteins | 5 | 2013 | 646 | 0.600 |
Why?
|
| Macrophages | 8 | 2020 | 1541 | 0.580 |
Why?
|
| Phosphorylation | 13 | 2020 | 1756 | 0.570 |
Why?
|
| Bronchitis | 2 | 2019 | 44 | 0.550 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 5 | 2019 | 326 | 0.550 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2022 | 916 | 0.520 |
Why?
|
| Pulmonary Medicine | 3 | 2013 | 85 | 0.510 |
Why?
|
| Hyaluronan Receptors | 2 | 2007 | 103 | 0.510 |
Why?
|
| Lung Transplantation | 6 | 2006 | 308 | 0.510 |
Why?
|
| Cell Adhesion Molecules | 2 | 2016 | 181 | 0.500 |
Why?
|
| Health | 1 | 2016 | 84 | 0.490 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 8 | 2020 | 170 | 0.480 |
Why?
|
| Bronchoscopy | 1 | 2016 | 222 | 0.480 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 939 | 0.470 |
Why?
|
| Respiratory System | 1 | 2016 | 157 | 0.460 |
Why?
|
| Reactive Oxygen Species | 4 | 2006 | 618 | 0.440 |
Why?
|
| Immunity, Innate | 4 | 2011 | 826 | 0.440 |
Why?
|
| Matrix Metalloproteinases | 1 | 2014 | 94 | 0.430 |
Why?
|
| Cell Communication | 3 | 2013 | 314 | 0.420 |
Why?
|
| Lung Neoplasms | 5 | 2019 | 2491 | 0.420 |
Why?
|
| CCN Intercellular Signaling Proteins | 1 | 2013 | 5 | 0.410 |
Why?
|
| Cysteine-Rich Protein 61 | 1 | 2013 | 7 | 0.410 |
Why?
|
| Respiratory Tract Infections | 4 | 2014 | 396 | 0.410 |
Why?
|
| Phagosomes | 4 | 2010 | 44 | 0.400 |
Why?
|
| Calpain | 1 | 2013 | 59 | 0.400 |
Why?
|
| Mice, Inbred C57BL | 14 | 2021 | 5744 | 0.390 |
Why?
|
| Disease Models, Animal | 8 | 2022 | 4279 | 0.370 |
Why?
|
| Bacterial Infections | 3 | 2014 | 251 | 0.370 |
Why?
|
| Epithelium | 2 | 2011 | 311 | 0.370 |
Why?
|
| Atherosclerosis | 1 | 2016 | 415 | 0.370 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 6 | 2006 | 455 | 0.370 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 413 | 0.360 |
Why?
|
| Sepsis | 3 | 2006 | 611 | 0.360 |
Why?
|
| Biomarkers | 5 | 2021 | 4158 | 0.360 |
Why?
|
| Endothelium | 1 | 2011 | 122 | 0.350 |
Why?
|
| Protein Tyrosine Phosphatases, Non-Receptor | 5 | 2018 | 11 | 0.350 |
Why?
|
| Extracellular Matrix | 2 | 2015 | 527 | 0.350 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 2 | 2022 | 26 | 0.350 |
Why?
|
| Enzyme Inhibitors | 3 | 2011 | 838 | 0.340 |
Why?
|
| Sirolimus | 4 | 2019 | 275 | 0.330 |
Why?
|
| Cystic Fibrosis | 7 | 2019 | 1104 | 0.330 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2023 | 2677 | 0.330 |
Why?
|
| Neutrophil Activation | 3 | 2007 | 80 | 0.320 |
Why?
|
| src-Family Kinases | 3 | 2022 | 92 | 0.320 |
Why?
|
| Cell Adhesion | 8 | 2013 | 467 | 0.310 |
Why?
|
| Molecular Probe Techniques | 1 | 2009 | 10 | 0.310 |
Why?
|
| Inflammation | 11 | 2022 | 2834 | 0.300 |
Why?
|
| Pulmonary Alveolar Proteinosis | 1 | 2008 | 17 | 0.290 |
Why?
|
| Indoles | 1 | 2011 | 410 | 0.290 |
Why?
|
| Monocytes | 3 | 2021 | 561 | 0.290 |
Why?
|
| Receptor, PAR-2 | 1 | 2007 | 6 | 0.290 |
Why?
|
| Caveolin 1 | 1 | 2007 | 19 | 0.280 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2007 | 351 | 0.280 |
Why?
|
| Actins | 7 | 2023 | 415 | 0.280 |
Why?
|
| Macrophage-1 Antigen | 1 | 2007 | 28 | 0.280 |
Why?
|
| Enzyme Activation | 8 | 2020 | 813 | 0.280 |
Why?
|
| Cell Movement | 3 | 2013 | 969 | 0.280 |
Why?
|
| Transfection | 7 | 2009 | 945 | 0.270 |
Why?
|
| Stroke | 1 | 2016 | 1129 | 0.270 |
Why?
|
| Calcium Signaling | 6 | 2015 | 249 | 0.270 |
Why?
|
| Critical Care | 3 | 2017 | 583 | 0.270 |
Why?
|
| Fluorescent Dyes | 1 | 2009 | 318 | 0.270 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2022 | 530 | 0.260 |
Why?
|
| Endoplasmic Reticulum | 6 | 2015 | 264 | 0.260 |
Why?
|
| Reactive Nitrogen Species | 1 | 2006 | 21 | 0.260 |
Why?
|
| Dyspnea | 2 | 2019 | 251 | 0.250 |
Why?
|
| Cytoplasmic Granules | 2 | 2010 | 93 | 0.250 |
Why?
|
| RNA, Small Interfering | 7 | 2018 | 621 | 0.250 |
Why?
|
| Endothelial Cells | 1 | 2011 | 778 | 0.250 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 6 | 2010 | 23 | 0.250 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2019 | 130 | 0.250 |
Why?
|
| Peptide Hydrolases | 2 | 2022 | 111 | 0.240 |
Why?
|
| Pseudomonas Infections | 1 | 2007 | 224 | 0.240 |
Why?
|
| rac GTP-Binding Proteins | 4 | 2012 | 32 | 0.240 |
Why?
|
| Lipid Metabolism | 1 | 2009 | 512 | 0.240 |
Why?
|
| Radiography, Thoracic | 1 | 2006 | 168 | 0.240 |
Why?
|
| Platelet Activation | 1 | 2005 | 93 | 0.240 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 2 | 2015 | 34 | 0.230 |
Why?
|
| NF-kappa B | 1 | 2009 | 691 | 0.230 |
Why?
|
| Embryonic Development | 1 | 2005 | 118 | 0.230 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2004 | 365 | 0.230 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2003 | 313 | 0.230 |
Why?
|
| Permeability | 4 | 2012 | 162 | 0.230 |
Why?
|
| Mice, Knockout | 11 | 2018 | 2999 | 0.220 |
Why?
|
| Hypertension, Pulmonary | 1 | 2016 | 1902 | 0.220 |
Why?
|
| Gene Deletion | 4 | 2014 | 392 | 0.220 |
Why?
|
| Afghanistan | 5 | 2022 | 71 | 0.220 |
Why?
|
| Lung Injury | 3 | 2015 | 218 | 0.220 |
Why?
|
| Protein Binding | 12 | 2021 | 2223 | 0.210 |
Why?
|
| Collagen | 3 | 2020 | 445 | 0.210 |
Why?
|
| Breath Tests | 1 | 2004 | 87 | 0.210 |
Why?
|
| Spike Glycoprotein, Coronavirus | 2 | 2022 | 107 | 0.210 |
Why?
|
| Supreme Court Decisions | 1 | 2023 | 11 | 0.210 |
Why?
|
| NIH 3T3 Cells | 5 | 2014 | 144 | 0.210 |
Why?
|
| Disease Progression | 5 | 2019 | 2750 | 0.200 |
Why?
|
| Mitochondria, Muscle | 1 | 2004 | 116 | 0.200 |
Why?
|
| Arthritis | 1 | 2023 | 95 | 0.200 |
Why?
|
| Mastication | 1 | 2022 | 13 | 0.190 |
Why?
|
| Lymphocyte Activation | 2 | 2005 | 1150 | 0.190 |
Why?
|
| Employment | 1 | 2004 | 177 | 0.190 |
Why?
|
| Cytokines | 7 | 2018 | 2088 | 0.190 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2022 | 54 | 0.190 |
Why?
|
| Adenoviridae | 2 | 2014 | 193 | 0.190 |
Why?
|
| Rare Diseases | 1 | 2002 | 101 | 0.190 |
Why?
|
| Fibrosis | 2 | 2022 | 551 | 0.190 |
Why?
|
| MAP Kinase Signaling System | 3 | 2018 | 321 | 0.190 |
Why?
|
| Monitoring, Physiologic | 1 | 2004 | 267 | 0.190 |
Why?
|
| Cell Line | 6 | 2020 | 2836 | 0.190 |
Why?
|
| Sputum | 1 | 2004 | 311 | 0.190 |
Why?
|
| Tyrosine | 2 | 2017 | 222 | 0.180 |
Why?
|
| Female | 29 | 2020 | 72840 | 0.180 |
Why?
|
| Alveolar Epithelial Cells | 1 | 2022 | 114 | 0.180 |
Why?
|
| Burkholderia cenocepacia | 2 | 2011 | 3 | 0.180 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2022 | 804 | 0.180 |
Why?
|
| Research Report | 1 | 2022 | 83 | 0.180 |
Why?
|
| Animal Care Committees | 1 | 2021 | 6 | 0.180 |
Why?
|
| Animal Welfare | 1 | 2021 | 13 | 0.180 |
Why?
|
| Bronchoalveolar Lavage Fluid | 6 | 2021 | 654 | 0.180 |
Why?
|
| Animals, Laboratory | 1 | 2021 | 17 | 0.180 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 21 | 0.170 |
Why?
|
| Mutation | 6 | 2022 | 3953 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2009 | 436 | 0.170 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2020 | 27 | 0.170 |
Why?
|
| Gingiva | 4 | 2013 | 25 | 0.170 |
Why?
|
| Interleukin-33 | 1 | 2020 | 49 | 0.170 |
Why?
|
| Diagnosis, Differential | 2 | 2023 | 1483 | 0.160 |
Why?
|
| Interleukin-8 | 3 | 2018 | 267 | 0.160 |
Why?
|
| Leucine | 1 | 2020 | 111 | 0.160 |
Why?
|
| Cadherins | 2 | 2011 | 205 | 0.160 |
Why?
|
| Rats | 10 | 2011 | 5628 | 0.160 |
Why?
|
| Aerosols | 1 | 2020 | 176 | 0.160 |
Why?
|
| Immunoblotting | 4 | 2011 | 307 | 0.160 |
Why?
|
| Proteolysis | 1 | 2020 | 178 | 0.160 |
Why?
|
| Blood Transfusion | 1 | 2002 | 324 | 0.160 |
Why?
|
| Microfilament Proteins | 1 | 2020 | 131 | 0.160 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 3 | 2015 | 28 | 0.160 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2019 | 15 | 0.160 |
Why?
|
| Directed Molecular Evolution | 1 | 2019 | 26 | 0.150 |
Why?
|
| Lymphocytes | 3 | 2006 | 395 | 0.150 |
Why?
|
| Inflammasomes | 2 | 2018 | 128 | 0.150 |
Why?
|
| Iraq War, 2003-2011 | 1 | 2019 | 127 | 0.150 |
Why?
|
| Fibronectins | 2 | 2012 | 133 | 0.150 |
Why?
|
| Intestinal Mucosa | 1 | 2004 | 620 | 0.150 |
Why?
|
| Afghan Campaign 2001- | 1 | 2019 | 132 | 0.150 |
Why?
|
| Transplantation, Heterologous | 3 | 2005 | 195 | 0.150 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2011 | 284 | 0.150 |
Why?
|
| Male | 25 | 2020 | 67361 | 0.150 |
Why?
|
| Retinal Degeneration | 1 | 2018 | 38 | 0.150 |
Why?
|
| Actin Capping Proteins | 1 | 2018 | 1 | 0.150 |
Why?
|
| Allergens | 1 | 2021 | 407 | 0.140 |
Why?
|
| Pleural Diseases | 1 | 2017 | 23 | 0.140 |
Why?
|
| Interleukin-13 | 1 | 2018 | 149 | 0.140 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2014 | 429 | 0.140 |
Why?
|
| Consensus | 1 | 2021 | 679 | 0.140 |
Why?
|
| Vascular Endothelial Growth Factor D | 2 | 2016 | 13 | 0.140 |
Why?
|
| Calcium | 5 | 2014 | 1197 | 0.140 |
Why?
|
| Middle Aged | 18 | 2020 | 33200 | 0.140 |
Why?
|
| Adult | 19 | 2020 | 37616 | 0.140 |
Why?
|
| Actinin | 2 | 2008 | 13 | 0.140 |
Why?
|
| Defensins | 2 | 2008 | 4 | 0.140 |
Why?
|
| Paxillin | 2 | 2008 | 10 | 0.140 |
Why?
|
| Ischemic Preconditioning | 2 | 2010 | 40 | 0.130 |
Why?
|
| Oxidative Stress | 1 | 2003 | 1309 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 973 | 0.130 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2014 | 1242 | 0.130 |
Why?
|
| Intensive Care Units | 1 | 2002 | 802 | 0.130 |
Why?
|
| Microbial Viability | 2 | 2007 | 91 | 0.130 |
Why?
|
| Military Personnel | 2 | 2021 | 542 | 0.130 |
Why?
|
| Intraocular Pressure | 1 | 2018 | 305 | 0.130 |
Why?
|
| Caspase 3 | 2 | 2009 | 246 | 0.130 |
Why?
|
| Models, Biological | 5 | 2020 | 1769 | 0.120 |
Why?
|
| Tuberous Sclerosis | 2 | 2006 | 55 | 0.120 |
Why?
|
| Genetic Vectors | 2 | 2011 | 321 | 0.120 |
Why?
|
| Mitochondria | 3 | 2009 | 946 | 0.120 |
Why?
|
| Inflammation Mediators | 3 | 2009 | 514 | 0.120 |
Why?
|
| Liposomes | 3 | 2009 | 220 | 0.120 |
Why?
|
| Glaucoma | 1 | 2018 | 234 | 0.120 |
Why?
|
| Secretory Vesicles | 2 | 2005 | 24 | 0.120 |
Why?
|
| CD11b Antigen | 4 | 2010 | 61 | 0.120 |
Why?
|
| Ligands | 3 | 2022 | 664 | 0.120 |
Why?
|
| Phospholipase C gamma | 2 | 2013 | 29 | 0.120 |
Why?
|
| Influenza, Human | 1 | 2021 | 624 | 0.120 |
Why?
|
| RNA, Messenger | 6 | 2022 | 2831 | 0.120 |
Why?
|
| Antiviral Agents | 1 | 2021 | 736 | 0.110 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 3 | 2020 | 30 | 0.110 |
Why?
|
| Gene Expression Regulation | 4 | 2020 | 2603 | 0.110 |
Why?
|
| Genes, Reporter | 2 | 2014 | 268 | 0.110 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2014 | 132 | 0.110 |
Why?
|
| Catalytic Domain | 2 | 2019 | 226 | 0.110 |
Why?
|
| Receptors, CXCR4 | 2 | 2006 | 85 | 0.110 |
Why?
|
| Severity of Illness Index | 4 | 2018 | 2831 | 0.110 |
Why?
|
| Pancreatic Elastase | 2 | 2006 | 58 | 0.110 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2014 | 219 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2006 | 327 | 0.110 |
Why?
|
| Smad Proteins | 1 | 2014 | 42 | 0.110 |
Why?
|
| Transcription Factors | 1 | 2022 | 1714 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2020 | 689 | 0.110 |
Why?
|
| Attitude of Health Personnel | 1 | 2002 | 1157 | 0.110 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2014 | 59 | 0.110 |
Why?
|
| Chemotaxis, Leukocyte | 5 | 2006 | 138 | 0.110 |
Why?
|
| Mice, Transgenic | 4 | 2014 | 2162 | 0.110 |
Why?
|
| Respiratory Function Tests | 2 | 2006 | 596 | 0.110 |
Why?
|
| Interleukin-1beta | 2 | 2013 | 372 | 0.110 |
Why?
|
| Caspases | 2 | 2005 | 247 | 0.110 |
Why?
|
| Toll-Like Receptors | 1 | 2014 | 185 | 0.110 |
Why?
|
| Connective Tissue | 1 | 2013 | 36 | 0.110 |
Why?
|
| Asthma | 3 | 2019 | 2290 | 0.100 |
Why?
|
| ras-GRF1 | 1 | 2013 | 2 | 0.100 |
Why?
|
| ras Guanine Nucleotide Exchange Factors | 1 | 2013 | 8 | 0.100 |
Why?
|
| United States | 5 | 2023 | 14660 | 0.100 |
Why?
|
| Periodontitis | 1 | 2013 | 52 | 0.100 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2013 | 11 | 0.100 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2012 | 209 | 0.100 |
Why?
|
| Gene Expression | 4 | 2013 | 1499 | 0.100 |
Why?
|
| Gap Junctions | 1 | 2013 | 59 | 0.100 |
Why?
|
| Eosinophils | 2 | 2008 | 331 | 0.100 |
Why?
|
| Cell-Derived Microparticles | 1 | 2013 | 71 | 0.100 |
Why?
|
| Homeostasis | 1 | 2016 | 618 | 0.100 |
Why?
|
| Coculture Techniques | 1 | 2013 | 239 | 0.100 |
Why?
|
| Neuropeptides | 1 | 2012 | 74 | 0.090 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2011 | 22 | 0.090 |
Why?
|
| Protein Transport | 2 | 2011 | 442 | 0.090 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2011 | 56 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2006 | 495 | 0.090 |
Why?
|
| Cyclin D1 | 1 | 2011 | 67 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2011 | 765 | 0.090 |
Why?
|
| Aged | 9 | 2019 | 23729 | 0.090 |
Why?
|
| Actin Cytoskeleton | 1 | 2011 | 100 | 0.090 |
Why?
|
| Burkholderia Infections | 1 | 2010 | 4 | 0.090 |
Why?
|
| Macrophages, Alveolar | 1 | 2014 | 392 | 0.090 |
Why?
|
| Prognosis | 3 | 2009 | 4018 | 0.090 |
Why?
|
| ras Proteins | 1 | 2011 | 151 | 0.080 |
Why?
|
| Receptors, IgG | 5 | 2009 | 75 | 0.080 |
Why?
|
| Rats, Wistar | 2 | 2009 | 454 | 0.080 |
Why?
|
| Transgenes | 2 | 2008 | 179 | 0.080 |
Why?
|
| Histological Techniques | 1 | 2010 | 40 | 0.080 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2010 | 75 | 0.080 |
Why?
|
| Microscopy, Confocal | 2 | 2009 | 322 | 0.080 |
Why?
|
| Membrane Potentials | 2 | 2008 | 283 | 0.080 |
Why?
|
| Flow Cytometry | 4 | 2006 | 1181 | 0.080 |
Why?
|
| Pneumothorax | 2 | 2006 | 38 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 1568 | 0.080 |
Why?
|
| RNA Interference | 1 | 2011 | 464 | 0.080 |
Why?
|
| Cell Culture Techniques | 2 | 2009 | 363 | 0.080 |
Why?
|
| alpha-Defensins | 1 | 2009 | 10 | 0.080 |
Why?
|
| Exocytosis | 2 | 2010 | 89 | 0.080 |
Why?
|
| Blotting, Western | 2 | 2009 | 1225 | 0.080 |
Why?
|
| Survivors | 1 | 2013 | 487 | 0.080 |
Why?
|
| Amino Acyl-tRNA Synthetases | 1 | 2009 | 30 | 0.080 |
Why?
|
| Antibodies, Antinuclear | 1 | 2009 | 71 | 0.080 |
Why?
|
| Antibodies, Neutralizing | 2 | 2022 | 282 | 0.080 |
Why?
|
| Forced Expiratory Volume | 3 | 2019 | 532 | 0.080 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2009 | 56 | 0.080 |
Why?
|
| Membrane Fusion | 2 | 2010 | 39 | 0.080 |
Why?
|
| Chloride Channels | 1 | 2009 | 35 | 0.080 |
Why?
|
| Ion Transport | 1 | 2009 | 60 | 0.080 |
Why?
|
| Idiopathic Interstitial Pneumonias | 1 | 2009 | 49 | 0.080 |
Why?
|
| Bronchi | 3 | 2005 | 260 | 0.080 |
Why?
|
| ErbB Receptors | 1 | 2012 | 613 | 0.080 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2009 | 123 | 0.080 |
Why?
|
| Electric Impedance | 1 | 2009 | 107 | 0.070 |
Why?
|
| Retroviridae | 1 | 2008 | 99 | 0.070 |
Why?
|
| Connective Tissue Diseases | 1 | 2009 | 83 | 0.070 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2009 | 345 | 0.070 |
Why?
|
| Biological Assay | 1 | 2009 | 123 | 0.070 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2009 | 188 | 0.070 |
Why?
|
| Egtazic Acid | 2 | 2005 | 40 | 0.070 |
Why?
|
| Cell Membrane | 3 | 2012 | 736 | 0.070 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 1 | 2007 | 54 | 0.070 |
Why?
|
| Protein Domains | 2 | 2020 | 289 | 0.070 |
Why?
|
| Caveolae | 1 | 2007 | 17 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2009 | 386 | 0.070 |
Why?
|
| Cell Polarity | 1 | 2009 | 141 | 0.070 |
Why?
|
| rap1 GTP-Binding Proteins | 1 | 2007 | 4 | 0.070 |
Why?
|
| CD18 Antigens | 1 | 2007 | 26 | 0.070 |
Why?
|
| Bronchiectasis | 1 | 2009 | 111 | 0.070 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2011 | 412 | 0.070 |
Why?
|
| Antigens, CD | 3 | 2010 | 522 | 0.070 |
Why?
|
| Dendritic Cells | 2 | 2008 | 484 | 0.070 |
Why?
|
| Glomerulonephritis | 1 | 2008 | 47 | 0.070 |
Why?
|
| Transcription, Genetic | 1 | 2014 | 1453 | 0.070 |
Why?
|
| Blood Platelets | 2 | 2013 | 405 | 0.070 |
Why?
|
| Bone Marrow | 1 | 2008 | 286 | 0.070 |
Why?
|
| Cell Line, Tumor | 2 | 2012 | 3399 | 0.070 |
Why?
|
| Fibrinogen | 1 | 2008 | 168 | 0.070 |
Why?
|
| Murine hepatitis virus | 1 | 2006 | 16 | 0.070 |
Why?
|
| Chemokines | 1 | 2008 | 228 | 0.070 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2006 | 14 | 0.070 |
Why?
|
| Aircraft | 1 | 2006 | 22 | 0.070 |
Why?
|
| Aerospace Medicine | 1 | 2006 | 27 | 0.070 |
Why?
|
| Binding Sites | 2 | 2021 | 1308 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 3 | 2004 | 397 | 0.060 |
Why?
|
| Mast Cells | 1 | 2008 | 146 | 0.060 |
Why?
|
| Vanadates | 1 | 2006 | 14 | 0.060 |
Why?
|
| Regenerative Medicine | 1 | 2006 | 47 | 0.060 |
Why?
|
| Syk Kinase | 1 | 2006 | 21 | 0.060 |
Why?
|
| Oligopeptides | 2 | 2005 | 272 | 0.060 |
Why?
|
| Diuretics | 1 | 2006 | 74 | 0.060 |
Why?
|
| Subcellular Fractions | 2 | 2006 | 82 | 0.060 |
Why?
|
| Respiratory Burst | 1 | 2005 | 16 | 0.060 |
Why?
|
| Cell Survival | 2 | 2006 | 1117 | 0.060 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2005 | 23 | 0.060 |
Why?
|
| Cerebral Infarction | 1 | 2005 | 43 | 0.060 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2011 | 2481 | 0.060 |
Why?
|
| Endothelium, Vascular | 3 | 2013 | 925 | 0.060 |
Why?
|
| Bone Development | 1 | 2005 | 54 | 0.060 |
Why?
|
| Spirometry | 1 | 2006 | 281 | 0.060 |
Why?
|
| Amino Acid Sequence | 2 | 2020 | 2145 | 0.060 |
Why?
|
| Osmolar Concentration | 1 | 2005 | 170 | 0.060 |
Why?
|
| Travel | 1 | 2006 | 129 | 0.060 |
Why?
|
| Drug Design | 1 | 2006 | 166 | 0.060 |
Why?
|
| Caspase 9 | 1 | 2005 | 57 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2012 | 936 | 0.060 |
Why?
|
| Immunity | 1 | 2006 | 144 | 0.060 |
Why?
|
| Neural Tube Defects | 1 | 2005 | 62 | 0.060 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2009 | 460 | 0.060 |
Why?
|
| Cyclic AMP | 1 | 2005 | 234 | 0.060 |
Why?
|
| Cytosol | 2 | 2004 | 226 | 0.060 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2005 | 162 | 0.060 |
Why?
|
| Structure-Activity Relationship | 2 | 2020 | 573 | 0.060 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2008 | 387 | 0.060 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2006 | 260 | 0.060 |
Why?
|
| Type C Phospholipases | 1 | 2004 | 74 | 0.060 |
Why?
|
| Platelet Activating Factor | 1 | 2004 | 76 | 0.060 |
Why?
|
| Drosophila melanogaster | 1 | 2006 | 228 | 0.060 |
Why?
|
| Time Factors | 5 | 2014 | 6792 | 0.060 |
Why?
|
| Neovascularization, Physiologic | 1 | 2005 | 177 | 0.060 |
Why?
|
| Phospholipases A | 1 | 2004 | 102 | 0.060 |
Why?
|
| Gene Knockdown Techniques | 2 | 2018 | 326 | 0.060 |
Why?
|
| Escherichia coli | 2 | 2005 | 812 | 0.060 |
Why?
|
| NADPH Oxidases | 1 | 2004 | 110 | 0.060 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2004 | 72 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 1768 | 0.050 |
Why?
|
| Developing Countries | 1 | 2006 | 306 | 0.050 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2004 | 82 | 0.050 |
Why?
|
| Vas Deferens | 1 | 2003 | 12 | 0.050 |
Why?
|
| Chemotaxis | 1 | 2004 | 130 | 0.050 |
Why?
|
| Leukotriene Antagonists | 1 | 2004 | 43 | 0.050 |
Why?
|
| Quality of Life | 2 | 2013 | 2868 | 0.050 |
Why?
|
| Autoimmune Diseases | 1 | 2008 | 459 | 0.050 |
Why?
|
| Muscle, Smooth | 1 | 2004 | 155 | 0.050 |
Why?
|
| Biopsy | 2 | 2017 | 1126 | 0.050 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2004 | 98 | 0.050 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2023 | 67 | 0.050 |
Why?
|
| L-Selectin | 1 | 2003 | 26 | 0.050 |
Why?
|
| Survival Rate | 2 | 2011 | 1969 | 0.050 |
Why?
|
| Vitamin E | 1 | 2003 | 121 | 0.050 |
Why?
|
| Metalloendopeptidases | 1 | 2003 | 62 | 0.050 |
Why?
|
| Chromans | 1 | 2003 | 25 | 0.050 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2004 | 133 | 0.050 |
Why?
|
| 3T3 Cells | 1 | 2003 | 163 | 0.050 |
Why?
|
| Electrocardiography | 1 | 2006 | 628 | 0.050 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2006 | 389 | 0.050 |
Why?
|
| Lung Compliance | 2 | 2014 | 49 | 0.050 |
Why?
|
| Sampling Studies | 1 | 2002 | 100 | 0.050 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2003 | 87 | 0.050 |
Why?
|
| Transposases | 1 | 2022 | 20 | 0.050 |
Why?
|
| Models, Animal | 2 | 2021 | 384 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2005 | 400 | 0.050 |
Why?
|
| Matrix Metalloproteinase 10 | 1 | 2022 | 3 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2019 | 5718 | 0.050 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 126 | 0.050 |
Why?
|
| Perception | 1 | 2005 | 356 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2020 | 3429 | 0.050 |
Why?
|
| Oxidation-Reduction | 1 | 2006 | 1062 | 0.050 |
Why?
|
| Hemagglutinins | 1 | 2001 | 9 | 0.050 |
Why?
|
| U937 Cells | 1 | 2001 | 24 | 0.050 |
Why?
|
| HL-60 Cells | 1 | 2001 | 33 | 0.050 |
Why?
|
| Precipitin Tests | 1 | 2001 | 100 | 0.050 |
Why?
|
| Iraq | 1 | 2021 | 53 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2023 | 495 | 0.050 |
Why?
|
| Immunity, Humoral | 1 | 2022 | 117 | 0.050 |
Why?
|
| Phosphatidylinositol Phosphates | 1 | 2001 | 39 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2005 | 707 | 0.050 |
Why?
|
| Cricetinae | 3 | 2011 | 288 | 0.050 |
Why?
|
| Glutathione Transferase | 1 | 2001 | 104 | 0.050 |
Why?
|
| Kinetics | 2 | 2021 | 1668 | 0.050 |
Why?
|
| Educational Status | 1 | 2004 | 482 | 0.050 |
Why?
|
| Comorbidity | 1 | 2006 | 1611 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2006 | 359 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2004 | 350 | 0.050 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2021 | 55 | 0.050 |
Why?
|
| Age Factors | 2 | 2011 | 3290 | 0.050 |
Why?
|
| Staphylococcus aureus | 1 | 2005 | 452 | 0.050 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2021 | 52 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2005 | 439 | 0.040 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2021 | 93 | 0.040 |
Why?
|
| Vital Capacity | 2 | 2013 | 309 | 0.040 |
Why?
|
| Canada | 1 | 2002 | 420 | 0.040 |
Why?
|
| Veterinarians | 1 | 2021 | 11 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2005 | 723 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2005 | 620 | 0.040 |
Why?
|
| Protein Engineering | 1 | 2022 | 109 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2001 | 271 | 0.040 |
Why?
|
| Surface Plasmon Resonance | 1 | 2021 | 88 | 0.040 |
Why?
|
| Repetitive Sequences, Amino Acid | 1 | 2020 | 17 | 0.040 |
Why?
|
| Receptors, Virus | 1 | 2021 | 83 | 0.040 |
Why?
|
| Molecular Docking Simulation | 1 | 2021 | 112 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2004 | 5749 | 0.040 |
Why?
|
| Receptors, Interleukin-1 Type I | 1 | 2020 | 23 | 0.040 |
Why?
|
| Waiting Lists | 1 | 2002 | 262 | 0.040 |
Why?
|
| Cell-Penetrating Peptides | 1 | 2020 | 21 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2018 | 843 | 0.040 |
Why?
|
| Down-Regulation | 2 | 2018 | 657 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 82 | 0.040 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2021 | 151 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2005 | 615 | 0.040 |
Why?
|
| Middle East | 1 | 2019 | 15 | 0.040 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2004 | 393 | 0.040 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2019 | 59 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 7569 | 0.040 |
Why?
|
| Motivation | 1 | 2004 | 563 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2004 | 3272 | 0.040 |
Why?
|
| Antioxidants | 1 | 2003 | 578 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 2002 | 696 | 0.040 |
Why?
|
| Particle Size | 1 | 2020 | 394 | 0.040 |
Why?
|
| Adaptation, Physiological | 1 | 2003 | 546 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2001 | 663 | 0.040 |
Why?
|
| Health Status | 1 | 2004 | 781 | 0.040 |
Why?
|
| Bronchial Diseases | 1 | 2018 | 37 | 0.040 |
Why?
|
| Amino Acids | 1 | 2022 | 500 | 0.040 |
Why?
|
| Gliosis | 1 | 2018 | 28 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 451 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2019 | 328 | 0.040 |
Why?
|
| Premenopause | 1 | 2019 | 131 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2013 | 7583 | 0.040 |
Why?
|
| Optic Nerve | 1 | 2018 | 64 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 2004 | 914 | 0.040 |
Why?
|
| Chromatin | 1 | 2022 | 518 | 0.040 |
Why?
|
| Cough | 1 | 2019 | 121 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2002 | 642 | 0.040 |
Why?
|
| Respiratory Care Units | 1 | 2017 | 2 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2018 | 197 | 0.040 |
Why?
|
| Role | 1 | 2018 | 32 | 0.040 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2018 | 115 | 0.040 |
Why?
|
| Societies | 1 | 2017 | 40 | 0.040 |
Why?
|
| Japan | 1 | 2017 | 116 | 0.030 |
Why?
|
| Heterozygote | 1 | 2018 | 292 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 2 | 2014 | 867 | 0.030 |
Why?
|
| Retinal Ganglion Cells | 1 | 2018 | 110 | 0.030 |
Why?
|
| Cattle | 1 | 2020 | 981 | 0.030 |
Why?
|
| Pulmonary Alveoli | 1 | 2020 | 405 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 364 | 0.030 |
Why?
|
| Crystallography, X-Ray | 1 | 2019 | 485 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 658 | 0.030 |
Why?
|
| Neuroprotective Agents | 1 | 2018 | 132 | 0.030 |
Why?
|
| Bronchodilator Agents | 1 | 2019 | 248 | 0.030 |
Why?
|
| Phosphotyrosine | 2 | 2009 | 38 | 0.030 |
Why?
|
| Double-Blind Method | 2 | 2013 | 1981 | 0.030 |
Why?
|
| Tetraspanin 30 | 2 | 2010 | 10 | 0.030 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2018 | 99 | 0.030 |
Why?
|
| Platelet Membrane Glycoproteins | 2 | 2010 | 36 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2005 | 1998 | 0.030 |
Why?
|
| Genomics | 1 | 2022 | 790 | 0.030 |
Why?
|
| Postmenopause | 1 | 2019 | 365 | 0.030 |
Why?
|
| Liver | 1 | 2005 | 1938 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2019 | 10764 | 0.030 |
Why?
|
| Neutrophil Infiltration | 2 | 2009 | 107 | 0.030 |
Why?
|
| Microglia | 1 | 2018 | 251 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2002 | 1455 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2019 | 940 | 0.030 |
Why?
|
| Complement Activation | 1 | 2018 | 411 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 849 | 0.030 |
Why?
|
| Microscopy, Electron | 2 | 2006 | 432 | 0.030 |
Why?
|
| Chemokines, CXC | 2 | 2006 | 70 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2008 | 233 | 0.030 |
Why?
|
| Acute Disease | 1 | 2018 | 1006 | 0.030 |
Why?
|
| Chemokine CXCL12 | 2 | 2006 | 80 | 0.030 |
Why?
|
| RNA | 1 | 2001 | 924 | 0.030 |
Why?
|
| Neuronal Apoptosis-Inhibitory Protein | 1 | 2014 | 3 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2018 | 1319 | 0.030 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2014 | 21 | 0.030 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 2014 | 11 | 0.030 |
Why?
|
| Hydroxyproline | 1 | 2014 | 21 | 0.030 |
Why?
|
| Nod1 Signaling Adaptor Protein | 1 | 2014 | 12 | 0.030 |
Why?
|
| Nod2 Signaling Adaptor Protein | 1 | 2014 | 33 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2004 | 1799 | 0.030 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 2014 | 28 | 0.030 |
Why?
|
| fas Receptor | 1 | 2014 | 95 | 0.030 |
Why?
|
| Alveolar Bone Loss | 1 | 2013 | 8 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2002 | 1294 | 0.030 |
Why?
|
| Brain | 1 | 2005 | 2669 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 2013 | 90 | 0.030 |
Why?
|
| Remission Induction | 1 | 2014 | 287 | 0.030 |
Why?
|
| Calcium Channels | 2 | 2004 | 159 | 0.030 |
Why?
|
| Exercise | 1 | 2005 | 2038 | 0.030 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2014 | 151 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 2014 | 218 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 1942 | 0.020 |
Why?
|
| Mesocricetus | 2 | 2003 | 39 | 0.020 |
Why?
|
| Talin | 1 | 2012 | 9 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2004 | 5417 | 0.020 |
Why?
|
| Rats, Inbred Lew | 2 | 2003 | 114 | 0.020 |
Why?
|
| Pandemics | 1 | 2021 | 1619 | 0.020 |
Why?
|
| Integrin beta1 | 1 | 2012 | 25 | 0.020 |
Why?
|
| ADAM17 Protein | 1 | 2012 | 35 | 0.020 |
Why?
|
| Base Sequence | 2 | 2006 | 2180 | 0.020 |
Why?
|
| Membrane Proteins | 2 | 2012 | 1162 | 0.020 |
Why?
|
| ADAM Proteins | 1 | 2012 | 61 | 0.020 |
Why?
|
| Vimentin | 1 | 2012 | 52 | 0.020 |
Why?
|
| Pinocytosis | 1 | 2011 | 10 | 0.020 |
Why?
|
| Adolescent | 3 | 2009 | 21463 | 0.020 |
Why?
|
| Oncogenes | 1 | 2012 | 116 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2012 | 174 | 0.020 |
Why?
|
| Chemokine CXCL1 | 1 | 2011 | 76 | 0.020 |
Why?
|
| Erythrocytes | 2 | 2009 | 692 | 0.020 |
Why?
|
| Mesoderm | 1 | 2012 | 144 | 0.020 |
Why?
|
| Cricetulus | 1 | 2011 | 109 | 0.020 |
Why?
|
| In Vitro Techniques | 2 | 2003 | 1089 | 0.020 |
Why?
|
| CHO Cells | 1 | 2011 | 160 | 0.020 |
Why?
|
| Observation | 1 | 2011 | 50 | 0.020 |
Why?
|
| Trauma Severity Indices | 1 | 2011 | 106 | 0.020 |
Why?
|
| Intention to Treat Analysis | 1 | 2011 | 73 | 0.020 |
Why?
|
| Oxygen | 2 | 2006 | 933 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 2010 | 83 | 0.020 |
Why?
|
| Stem Cells | 1 | 2015 | 590 | 0.020 |
Why?
|
| Guanosine Triphosphate | 1 | 2010 | 91 | 0.020 |
Why?
|
| Endotoxins | 1 | 2011 | 220 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2014 | 768 | 0.020 |
Why?
|
| Adenoma | 1 | 2012 | 230 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2014 | 655 | 0.020 |
Why?
|
| Stress Fibers | 1 | 2009 | 19 | 0.020 |
Why?
|
| Risk Factors | 1 | 2004 | 10331 | 0.020 |
Why?
|
| Alanine-tRNA Ligase | 1 | 2009 | 4 | 0.020 |
Why?
|
| Amiloride | 1 | 2009 | 26 | 0.020 |
Why?
|
| Threonine-tRNA Ligase | 1 | 2009 | 5 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 2010 | 534 | 0.020 |
Why?
|
| Mammary Glands, Animal | 1 | 2010 | 129 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 432 | 0.020 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2009 | 86 | 0.020 |
Why?
|
| Virulence Factors | 1 | 2010 | 166 | 0.020 |
Why?
|
| Granulocytes | 1 | 2008 | 80 | 0.020 |
Why?
|
| Syndrome | 1 | 2009 | 357 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2008 | 298 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2011 | 468 | 0.020 |
Why?
|
| Receptors, CCR7 | 1 | 2006 | 32 | 0.020 |
Why?
|
| Mice, Inbred A | 1 | 2006 | 49 | 0.020 |
Why?
|
| Receptors, Chemokine | 1 | 2006 | 47 | 0.020 |
Why?
|
| Receptors, CCR5 | 1 | 2006 | 59 | 0.020 |
Why?
|
| Thymus Gland | 1 | 2008 | 313 | 0.020 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2006 | 47 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2006 | 269 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2006 | 269 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2012 | 1396 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2011 | 763 | 0.020 |
Why?
|
| Colforsin | 1 | 2005 | 53 | 0.020 |
Why?
|
| Hypoglossal Nerve | 1 | 2005 | 24 | 0.020 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2005 | 121 | 0.020 |
Why?
|
| Antibodies | 1 | 2008 | 412 | 0.020 |
Why?
|
| Spleen | 1 | 2008 | 513 | 0.020 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2005 | 111 | 0.010 |
Why?
|
| Species Specificity | 1 | 2006 | 584 | 0.010 |
Why?
|
| Stem Cell Transplantation | 1 | 2006 | 177 | 0.010 |
Why?
|
| Sex Factors | 1 | 2011 | 2068 | 0.010 |
Why?
|
| Interferons | 1 | 2006 | 199 | 0.010 |
Why?
|
| Calnexin | 1 | 2004 | 3 | 0.010 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2005 | 39 | 0.010 |
Why?
|
| Macrocyclic Compounds | 1 | 2004 | 9 | 0.010 |
Why?
|
| E-Selectin | 1 | 2005 | 57 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2008 | 492 | 0.010 |
Why?
|
| Polylysine | 1 | 2004 | 17 | 0.010 |
Why?
|
| Mitochondrial Membranes | 1 | 2005 | 38 | 0.010 |
Why?
|
| Ionomycin | 1 | 2004 | 23 | 0.010 |
Why?
|
| Leukotriene B4 | 1 | 2004 | 42 | 0.010 |
Why?
|
| N-Ethylmaleimide-Sensitive Proteins | 1 | 2004 | 5 | 0.010 |
Why?
|
| Oxazoles | 1 | 2004 | 37 | 0.010 |
Why?
|
| Phospholipases A2 | 1 | 2004 | 80 | 0.010 |
Why?
|
| Inositol Phosphates | 1 | 2004 | 22 | 0.010 |
Why?
|
| Colorado | 1 | 2015 | 4491 | 0.010 |
Why?
|
| Young Adult | 2 | 2013 | 13126 | 0.010 |
Why?
|
| Qa-SNARE Proteins | 1 | 2004 | 20 | 0.010 |
Why?
|
| Chelating Agents | 1 | 2005 | 75 | 0.010 |
Why?
|
| Chemotactic Factors | 1 | 2004 | 56 | 0.010 |
Why?
|
| Group IV Phospholipases A2 | 1 | 2004 | 47 | 0.010 |
Why?
|
| Protein Phosphatase 2 | 1 | 2004 | 41 | 0.010 |
Why?
|
| Immunoprecipitation | 1 | 2004 | 155 | 0.010 |
Why?
|
| Health Surveys | 1 | 2006 | 517 | 0.010 |
Why?
|
| Arachidonic Acid | 1 | 2004 | 120 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 2004 | 134 | 0.010 |
Why?
|
| Intracellular Membranes | 1 | 2004 | 84 | 0.010 |
Why?
|
| Molecular Motor Proteins | 1 | 2004 | 35 | 0.010 |
Why?
|
| Pyrrolidines | 1 | 2004 | 80 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 2004 | 153 | 0.010 |
Why?
|
| Microspheres | 1 | 2004 | 137 | 0.010 |
Why?
|
| Osteonectin | 1 | 2003 | 2 | 0.010 |
Why?
|
| Vesicular Transport Proteins | 1 | 2004 | 84 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2006 | 1267 | 0.010 |
Why?
|
| Tenascin | 1 | 2003 | 14 | 0.010 |
Why?
|
| Child | 1 | 2004 | 21968 | 0.010 |
Why?
|
| Ascitic Fluid | 1 | 2003 | 15 | 0.010 |
Why?
|
| Complement Hemolytic Activity Assay | 1 | 2003 | 2 | 0.010 |
Why?
|
| Serotonin | 1 | 2005 | 323 | 0.010 |
Why?
|
| Body Weight | 1 | 2008 | 981 | 0.010 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 2003 | 22 | 0.010 |
Why?
|
| Crosses, Genetic | 1 | 2003 | 137 | 0.010 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2003 | 31 | 0.010 |
Why?
|
| bcl-X Protein | 1 | 2003 | 43 | 0.010 |
Why?
|
| Cytoprotection | 1 | 2003 | 56 | 0.010 |
Why?
|
| Complement Inactivator Proteins | 1 | 2003 | 42 | 0.010 |
Why?
|
| Heme Oxygenase-1 | 1 | 2003 | 64 | 0.010 |
Why?
|
| Cell Count | 1 | 2003 | 321 | 0.010 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2005 | 220 | 0.010 |
Why?
|
| Clone Cells | 1 | 2003 | 266 | 0.010 |
Why?
|
| Leukocytes | 1 | 2004 | 312 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2004 | 564 | 0.010 |
Why?
|
| Peritonitis | 1 | 2003 | 84 | 0.010 |
Why?
|
| Superoxides | 1 | 2003 | 202 | 0.010 |
Why?
|
| beta-N-Acetylhexosaminidases | 1 | 2002 | 11 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 2005 | 486 | 0.010 |
Why?
|
| Oxidants | 1 | 2003 | 110 | 0.010 |
Why?
|
| Chemokine CCL5 | 1 | 2002 | 43 | 0.010 |
Why?
|
| Swine | 1 | 2005 | 773 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 2847 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2008 | 846 | 0.010 |
Why?
|
| Tissue Engineering | 1 | 2006 | 418 | 0.010 |
Why?
|
| Reperfusion Injury | 1 | 2004 | 278 | 0.010 |
Why?
|
| Aging | 1 | 2012 | 1861 | 0.010 |
Why?
|
| Plasmids | 1 | 2003 | 362 | 0.010 |
Why?
|
| Anastomosis, Surgical | 1 | 2002 | 152 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2009 | 3537 | 0.010 |
Why?
|
| Erythropoietin | 1 | 2002 | 95 | 0.010 |
Why?
|
| Hydrogen Peroxide | 1 | 2003 | 320 | 0.010 |
Why?
|
| Heart Atria | 1 | 2002 | 136 | 0.010 |
Why?
|
| Complement System Proteins | 1 | 2004 | 327 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2008 | 1980 | 0.010 |
Why?
|
| Pulmonary Veins | 1 | 2002 | 99 | 0.010 |
Why?
|
| Graft Survival | 1 | 2003 | 533 | 0.010 |
Why?
|
| Trachea | 1 | 2002 | 235 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 2045 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2002 | 377 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2002 | 1318 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 2005 | 918 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2002 | 778 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2003 | 890 | 0.010 |
Why?
|
| Phenotype | 1 | 2006 | 3199 | 0.010 |
Why?
|
| Myocardium | 1 | 2003 | 1002 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2006 | 5115 | 0.010 |
Why?
|
| Heart Transplantation | 1 | 2003 | 747 | 0.010 |
Why?
|
| Pulmonary Artery | 1 | 2002 | 1082 | 0.010 |
Why?
|